Corvus Pharmaceuticals (CRVS) Cash from Operations Growth (1y) (2016 - 2026)

Corvus Pharmaceuticals (CRVS) Cash from Operations Growth (1y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 7.14%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 356.73%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.23%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Corvus Pharmaceuticals 1.17 Bn 934.14 Mn - -25.55%

Historic Data

Download Data
DateValue
Mar 31, 2026 -25.55%
Dec 31, 2025 -8.58%
Sep 30, 2025 -51.34%
Jun 30, 2025 -5.40%
Mar 31, 2025 -60.23%
Dec 31, 2024 -63.83%
Sep 30, 2024 -16.32%
Jun 30, 2024 -4.94%
Mar 31, 2024 36.42%
Dec 31, 2023 31.54%
Sep 30, 2023 21.58%
Jun 30, 2023 14.70%
Mar 31, 2023 -26.26%
Dec 31, 2022 -10.32%
Sep 30, 2022 17.76%
Jun 30, 2022 51.59%
Mar 31, 2022 26.89%
Dec 31, 2021 16.64%
Sep 30, 2021 -8.96%
Jun 30, 2021 -33.32%